Cargando…

Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies

Despite the remarkable success of autologous chimeric antigen receptor (CAR) T cells, some patients relapse due to tumor antigen escape and low or uneven antigen expression, among other mechanisms. Therapeutic options after relapse are limited, emphasizing the need to optimize current approaches. In...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aranda-Orgilles, Beatriz, Chion-Sotinel, Isabelle, Skinner, Jordan, Grudman, Steven, Mumford, Ben, Dixon, Chantel, Postigo Fernandez, Jorge, Erler, Piril, Duchateau, Phillipe, Gouble, Agnes, Galetto, Roman, Poirot, Laurent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320475/ https://www.ncbi.nlm.nih.gov/pubmed/37257169 http://dx.doi.org/10.1158/2326-6066.CIR-22-0910

Ejemplares similares

P1420: PRE-CLINICAL PROOF OF CONCEPT DEMONSTRATES ROBUST ACTIVITY OF UCART20X22 DUAL CAR T-CELLS FOR THE TREATMENT OF B-CELL MALIGNANCIES
por: Aranda Orgilles, B., et al.
Publicado: (2022)

Treatment of B cells malignancies with anti-CD19 CAR+, TCR-, CD52- allogeneic T cells
por: Mannioui, Cécile Schiffer, et al.
Publicado: (2013)

Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing
por: Jo, Sumin, et al.
Publicado: (2022)

Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia
por: Sugita, Mayumi, et al.
Publicado: (2022)

Engineering tandem CD33xCD146 CAR CIK (cytokine-induced killer) cells to target the acute myeloid leukemia niche
por: Alberti, Gaia, et al.
Publicado: (2023)

Pre-TCRα supports CD3-dependent reactivation and expansion of TCRα-deficient primary human T-cells
por: Galetto, Román, et al.
Publicado: (2014)

Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells
por: Cai, Tianyu, et al.
Publicado: (2022)

Straightforward Generation of Ultrapure Off-the-Shelf Allogeneic CAR-T Cells
por: Juillerat, Alexandre, et al.
Publicado: (2020)

A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy
por: Valton, Julien, et al.
Publicado: (2015)

CD19xCD3 DART protein mediates human B-cell depletion in vivo in humanized BLT mice
por: Tsai, Perry, et al.
Publicado: (2016)

CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
por: Reusing, Sarah B., et al.
Publicado: (2021)

Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
por: Reusing, Sarah B., et al.
Publicado: (2021)

Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer
por: Liu, Huicheng, et al.
Publicado: (2021)

CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model
por: Chauchet, Xavier, et al.
Publicado: (2022)

A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL
por: Mehta, Naveen K, et al.
Publicado: (2022)

Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy
por: Das, Shipra, et al.
Publicado: (2023)

DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing
por: Engelberts, Patrick J., et al.
Publicado: (2020)

Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436
por: Uckun, Fatih M., et al.
Publicado: (2021)

Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody
por: Martini, Silvia, et al.
Publicado: (2020)

IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer
por: Lutz, Martina S., et al.
Publicado: (2023)

BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR‐T cell cytotoxicity
por: Poussard, Margaux, et al.
Publicado: (2020)

Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells
por: Fang, Karen Kai-Lin, et al.
Publicado: (2023)

Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies
por: Liu, Jun, et al.
Publicado: (2017)

CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells
por: Martens, Anne W J, et al.
Publicado: (2020)

A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
por: Uckun, Fatih M., et al.
Publicado: (2021)

P437: EFFECTIVE IMMUNOTHERAPY OF PEDIATRIC T(8;21) ACUTE MYELOID LEUKEMIA BY REPURPOSING CD3XCD19 TARGETING BISPECIFIC ANTIBODIES
por: Wijnen, Noa, et al.
Publicado: (2023)

Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells
por: MacLeod, Daniel T., et al.
Publicado: (2017)

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
por: Zhang, Yinqiang, et al.
Publicado: (2023)

Correction: CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells
Publicado: (2021)

Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells
por: Wathikthinnakon, Methi, et al.
Publicado: (2022)

Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA
por: Watts, Justin, et al.
Publicado: (2022)

Chromosomal context and epigenetic mechanisms control the efficacy of genome editing by rare-cutting designer endonucleases
por: Daboussi, Fayza, et al.
Publicado: (2012)

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial
por: Thieblemont, Catherine, et al.
Publicado: (2023)

Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia
por: Sánchez Martínez, Diego, et al.
Publicado: (2022)

Il-6 is non-essential to murine CD19 CAR efficacy, but can mediate acute GVHD following allogeneic BMT with CAR T cell infusion
por: Jacoby, Elad, et al.
Publicado: (2015)

Meganucleases and Other Tools for Targeted Genome Engineering: Perspectives and Challenges for Gene Therapy
por: Silva, George, et al.
Publicado: (2011)

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL
por: Fry, Terry J., et al.
Publicado: (2017)

An oxygen sensitive self-decision making engineered CAR T-cell
por: Juillerat, Alexandre, et al.
Publicado: (2017)

CD7 CAR: sword and shield
por: Velasquez, M. Paulina, et al.
Publicado: (2022)

Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
por: Li, Wenjie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1a0a60jqgi3nqkqats30aluc0m